Mavyret™ (glecaprevir/pibrentasvir) – Expanded indication
April 30, 2019, the FDA approved AbbVie’s Mavyret (glecaprevir/pibrentasvir), for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with Chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) and HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.
Top